gilead presid chief execut offic michael
riordan said compound gs504 first suit
experiment new drug gilead develop
nucleotid build block deoxyribonucl acid
dna raw materi gene
gs504 test cytomegalovirus cmv
virus frequent attack aid patient caus
inflamm retina eventu blind
anim studi suggest kidney toxic may side effect
drug side effect well
later year gilead plan file investig
new drug applic test second experiment drug
dub gs393 human immunodefici virus hiv
caus aid anim studi gs393 far appear
potent wellcom plc antivir drug azt dr
riordan said compound also inhibit herp virus
frequent companioninfect aid
dr. riordan say first two aids-rel drug may
given conveni oral formula also long
halflif activ stint bodi perhap enabl
doctor give less frequent dose emphas
guarante human safeti effect
nucleotid drug ever human yet say
five-year-old compani went public decemb gilead
one new wave biotech compani aim use
genet build block fight diseas differ way
establish biotech firm old biotech focus
product benefici protein re focus
turn disease-caus protein said dr. riordan
gs504 earmark gilead first time clinic
test three-part program treat diseas
viral infect heart diseas cancer program
organ around three kind experiment compound
increas size small molecul aid virus
medium-s strand heart diseas long strand
would block gene trigger cancer growth gilead
cancer work done pact glaxo inc
compani $ 105 million hand fund ambiti
research develop program dr. riordan said still
given long lead time arduous test requir
experiment drug gilead expect see
product revenu year said
